Researchers in Perth, West Australia will be testing a brand new weight-loss pill in the hope it will not only help people lose weight but also reduce their chance of heart diseases by increasing levels of good cholesterol or HDL.
Royal Perth Hospital test, as part of an international test, could prove the anti-obesity pill named Acomplia, developed by the French drugmaker Sanofi, can ward off the condition known as metabolic syndrome, a particularly high risk form of weight gain which entails problems controlling cholesterol, insulin and blood pressure.
Gerald Watts, RPH professor of medicine, who specialises in metabolic disturbances, said the medicine is expected to be sanctioned in Australia within a year and the hospital aimed to enrol 15 to 20 patients as part of the 80 being studied worldwide.
The drugs that have been available until now have had toxic effects and some work but have no long-term safety data, so this is a new approach to the controlling of weight gain.
The medicine works by blocking chemical processes in the brain, which results in reduced craving and also acts on the liver to help the body melt more fat, but side-effects can include nausea and diarrhea.
Were interested in the mechanism of how this medicine functions and the use it could play in fat people who have several hazard ingredients for heart disease, one of which is low HDL cholesterol, or metabolic syndrome, he said.
Professor Watts said the bottom line is to help people lose weight, which then reduces their risk of other maladies such as diabetes. It means that people end up eating less and burning more fat so its a very powerful tool for targeting obesity, but beyond that its also an powerful tool for curing smoking and even alcohol abuse, he said.
Royal Perth Hospital is enrolling men and women between 35 and 65 who are overweight or obese with a waist circumference of more than 40inches in men and 88cm in women and have high triglycerides with low HDL cholesterol. They will be put on a diet to lose 5 per cent of their body weight and some will be selected to continue on the Acomplia test.
In test that have been made, the gains that have been seen in terms of increasing HDL cholesterol could not be explained by the loss of weight alone, so it clearly has a direct consequence on the HDL cholesterol.
The author has been writing online articles since 2006 as well as publishing websites on a number of topics since 2004. Check out the latest website at http://jeanpaulgaultierfragrances.com which helps people find the best Jean Paul Gaultier fragrances deals as well as the information they might be searching for before purchasing designer fragrances.
Article Source:
http://www.goarticles.com/cgi-bin/showa.cgi?C=386023
Other articles you might like;
No related posts.